C. Lee
7 Papers
C. Lee is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
A. He,Juan W. Valle,C. Lee,Masahumi Ikeda,Piotr Potemski,Chigusa Morizane,J. Cundom,David Tougeron,Farshid Dayyani,Nana Rokutanda,J. Xiong,G. Cohen,D. Oh +12 more
TL;DR: Durvalumab plus gemcitabine and cisplatin (GemCis) as mentioned in this paper significantly improved overall survival (OS) versus placebo plus GemCis and represents a potential new first-line treatment option.
4
Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX
Charles Herbaux,S. Dietrich,Annabel McMillan,Catherine Thieblemont,Eva González-Barca,Antonio Pinto,Laura Fogliatto,Matthew J. Matasar,C. Lee,Juan Jesus Cruz hernandez,R. Ho,Aino Launonen,Frédéric Boissard +12 more
1
1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial
Federico Cappuzzo,Angelo Delmonte,Lorenza Landi,Kalliopi Andrikou,Alessandro Dal Maso,Gabriele Minuti,C. Lee,X. S. Wang,Mohammad Hassan Papi,Giulio Metro,Ilaria Attili,Francovito Piantedosi,Sara Pilotto,Sabrina Gori,G. Rossi,Simonetta Buglioni,Diana Giannarelli,Laura Bonanno +17 more
TL;DR: The SQUINT trial as mentioned in this paper was a randomized, prospective, phase II trial which assesses the efficacy of nivolumab plus investigator-choice platinum-based chemotherapy (N-CT) versus the combination of NI and ipilimumab (NI) in patients with advanced/metastatic non-small-cell lung cancer (NSCLC).
SO-7 First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study
TL;DR: In this article , the authors performed a multicenter, open-label, phase I/II study of a triplet regimen including nal-IRI, oxaliplatin and S-1 (NASOX) as first-line therapy in patients with unresectable or metastatic PDAC.